When combined with RV1B or RV29 infection in vivo, immunization generated more rapid and greater magnitude of RV-specific serum and BAL IgG responses, and BAL IgA responses, than RV-adjuvant treatment (Fig. S3a–d), indicating that immunization also boosts antibody responses upon subsequent heterotypic RV infection. Here, CD79A is linked to infection.